September 06, 2020
1 min read
Save
FDA clears Medacta’s lateralized glenosphere
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Medacta announced the company has received FDA clearance for its lateralized glenosphere implant for total shoulder arthroplasty.
The lateralized glenosphere, which received CE marking in 2019, is another option to Medacta’s shoulder system. The lateralized glenosphere has a more lateralized center of rotation compared to the standard glenosphere offered with the Medacta Shoulder System. According to a company press release, the potential benefits of a more lateralized construct include an improved range of motion and a reduced risk of scapular notching.
Published by:
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.